ERNAW · Ernexa Therapeutics Inc. · Financials
$0.03
0.00 (-1.54%)
At close · Oct 27
Return incl. dividend (before tax)
Going-concern doubt
— cleared Aug 6, 2026
The latest filing states the doubt was alleviated.
“As of June 30, 2026, the Company had approximately $5.0 million in cash, which is less than that needed to effect its current operating plan and forecasted cash requirements for the next twelve months. However, management expects that its ability to access capital under its ATM will cover shortfalls in its cash resources over the next twelve months from the issuance date of these financial statements.”View the 10-Q filed Aug 6, 2026
Market Cap
$3.25M
Shares
1.63M
Volume · Oct 27
1912
Avg daily vol (3M)
25.96K
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$582K
+755.9%
FY2024
Net Income
-$14.08M
+68.4%
FY2025
Gross Margin
83.51%
+330.6pp
FY2024
Operating Margin
-2693.13%
+28387.8pp
FY2024
Diluted EPS
-$56.00
+95.4%
FY2025
Operating Cash Flow
-$7.02M
+55.7%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | — | $582K | $68K | $0 | — | $5.8M | $19.81M | $23.34M | $21.27M | $22.31M | $24.52M | $26.05M | $23.75M | $24.06M | $23.87M | $25.31M | |
| — | — | $96K | $236K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | $486K | -$168K | $0 | — | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | 83.51% | -247.06% | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| $6.42M | $4.16M | $4.6M | $5.92M | $10.39M | $12.71M | $2000 | $26K | $72K | $139K | — | — | — | — | — | — | — | |
| $5.32M | $5.16M | $13.13M | $14.59M | $16.84M | $14.72M | $3.3M | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | $8.09M | $13.18M | $14.46M | $15.59M | $16.46M | $18.06M | $18.37M | $16.22M | $18.25M | $20.45M | $18.91M | |
| — | — | — | — | — | — | — | — | $29K | $29K | $50K | $50K | $181K | $418K | $378K | $614K | — | |
| -$345K | $65K | $139K | $84K | $161K | $117K | $98K | $2.88M | $2.76M | $2.32M | $2.89M | $3.1M | $2.75M | $2.85M | $2.88M | $3.26M | $3.2M | |
| $13.78M | $9.32M | $16.16M | $20.97M | $33.22M | $113.73M | $7.25M | $21.57M | $23.13M | $22.68M | $24.59M | $31.41M | $30.79M | $24.87M | $25.13M | $27.15M | $25.63M | |
| -$13.78M | -$9.32M | -$15.67M | -$21.14M | -$33.22M | -$113.73M | -$7.25M | -$1.76M | $203K | -$1.4M | -$2.28M | -$6.9M | -$4.74M | -$1.12M | -$1.06M | -$3.28M | -$325K | |
| — | — | -2693.13% | -31080.88% | — | — | -124.97% | -8.9% | 0.87% | -6.59% | -10.21% | -28.12% | -18.21% | -4.71% | -4.41% | -13.72% | -1.28% | |
| -$14.13M | -$9.25M | -$15.54M | -$21.05M | -$33.06M | -$113.62M | -$7.15M | $1.12M | $2.97M | $915K | $609K | -$3.79M | -$2M | $1.73M | $1.82M | -$16K | $2.88M | |
| — | -$100K | -$6.8M | $614K | $30K | — | — | — | — | — | — | — | $223K | $26K | $44K | $52K | $101K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | $3000 | $3000 | $3000 | |
| $1.43M | -$4.81M | -$28.84M | -$536K | $8.68M | -$8.75M | -$43K | -$258K | -$526K | $391K | -$607K | -$319K | -$204K | $112K | -$16K | $20K | -$33K | |
| -$12.35M | -$14.13M | -$44.51M | -$21.67M | -$24.53M | -$122.48M | -$7.29M | -$2.02M | -$323K | -$1.01M | -$2.89M | -$7.21M | -$4.95M | -$1.01M | -$1.08M | -$3.26M | — | |
| -$96K | -$45K | $30K | -$3000 | $45K | $64K | $0 | $27K | -$64K | $66K | $38K | $12K | $84K | $46K | -$83K | $163K | $42K | |
| -$12.26M | -$14.08M | -$44.54M | -$21.67M | -$24.58M | -$122.55M | -$7.29M | -$2.05M | -$259K | -$1.08M | -$2.92M | -$7.23M | -$5.03M | -$1.05M | -$995K | -$3.42M | -$400K | |
| — | — | -7652.75% | -31864.71% | — | — | -125.71% | -10.34% | -1.11% | -5.06% | -13.1% | -29.47% | -19.31% | -4.43% | -4.13% | -14.32% | -1.58% | |
| — | -$14.1M | -$44.56M | -$21.68M | -$24.6M | -$122.56M | -$7.29M | -$2.06M | -$275K | -$1.09M | — | — | — | — | — | — | — | |
| — | — | — | — | — | — | -$4.44M | -$1.98M | -$404K | -$955K | -$2.87M | -$7.53M | -$5.18M | -$1.19M | -$949K | -$3.48M | -$317K | |
| USD/shares | $6.60 | -$56.00 | -$1,224.00 | -$1,530.00 | -$3,022.50 | -$21,228.75 | -$3,075.00 | — | — | — | — | — | — | — | — | — | — |
| USD/shares | $6.60 | -$56.00 | -$1,224.00 | -$1,530.00 | -$3,022.50 | -$21,228.75 | -$3,075.00 | — | — | — | — | — | — | — | — | — | — |
| shares | — | 252.28K | 36.4K | 14.17K | 8136 | 5773.3333 | 2345.0667 | 0.1917 | 0.1792 | 162.8 | 126.8667 | 122.5333 | 5.8387 | 4797.4667 | 4.6027 | 4026.8 | 4008.9333 |
| shares | — | 252.28K | 36.4K | 14.17K | 8136 | 5773.3333 | 2345.0667 | 0.1917 | 0.1792 | 162.8 | 126.8667 | 122.5333 | 5.8387 | 4797.4667 | 4602.6667 | 4.0268 | — |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Operating lease liabilities | 2026-06-30 | USD 349,000 | 10-Q filed 2026-08-06 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.